WO2003023031A1 - Methode d'evaluation de l'efficacite d'une therapie aux acides nucleiques - Google Patents
Methode d'evaluation de l'efficacite d'une therapie aux acides nucleiques Download PDFInfo
- Publication number
- WO2003023031A1 WO2003023031A1 PCT/JP2002/008856 JP0208856W WO03023031A1 WO 2003023031 A1 WO2003023031 A1 WO 2003023031A1 JP 0208856 W JP0208856 W JP 0208856W WO 03023031 A1 WO03023031 A1 WO 03023031A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antitumor
- nucleic acid
- nucleoside
- nucleotide
- acid therapy
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 230000000840 anti-viral effect Effects 0.000 abstract 2
- 239000002777 nucleoside Substances 0.000 abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002203 pretreatment Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003527096A JPWO2003023031A1 (ja) | 2001-09-04 | 2002-09-02 | 核酸治療の有効性を診断する方法 |
| CA002459373A CA2459373A1 (en) | 2001-09-04 | 2002-09-02 | Method of evaluating efficacy of nucleic acid therapy |
| EP02762944A EP1435389A4 (en) | 2001-09-04 | 2002-09-02 | METHOD FOR EVALUATING THE EFFICACY OF NUCLEIC ACID THERAPY |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001267385 | 2001-09-04 | ||
| JP2001-267385 | 2001-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003023031A1 true WO2003023031A1 (fr) | 2003-03-20 |
Family
ID=19093520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2002/008856 WO2003023031A1 (fr) | 2001-09-04 | 2002-09-02 | Methode d'evaluation de l'efficacite d'une therapie aux acides nucleiques |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20030125285A1 (ja) |
| EP (1) | EP1435389A4 (ja) |
| JP (1) | JPWO2003023031A1 (ja) |
| CA (1) | CA2459373A1 (ja) |
| WO (1) | WO2003023031A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007269886A (ja) * | 2006-03-30 | 2007-10-18 | Fujifilm Corp | 感光性重合体、感光性組成物及び平版印刷版原版 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008109518A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting wnt gene expression and uses thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62252798A (ja) * | 1986-01-06 | 1987-11-04 | Nippon Shinyaku Co Ltd | 核酸誘導体 |
| JPH01238597A (ja) * | 1987-07-03 | 1989-09-22 | Nippon Shinyaku Co Ltd | 核酸誘導体 |
| WO1999020283A1 (fr) * | 1997-10-16 | 1999-04-29 | Nippon Shinyaku Co., Ltd. | Activateur de nuclease de cellules intracancereuses |
| WO1999048531A1 (fr) * | 1998-03-24 | 1999-09-30 | Nippon Shinyaku Co., Ltd. | Nouveaux remedes contre l'hepatite |
| WO1999061032A1 (fr) * | 1998-05-25 | 1999-12-02 | Nippon Shinyaku Co., Ltd. | Procede de production d'une preparation composite contenant de l'acide nucleique |
| WO2000060073A1 (fr) * | 1999-03-31 | 2000-10-12 | Sumitomo Pharmaceuticals Co., Ltd. | Gene de polypeptide irg27, anticorps contre ce polypeptide et son utilisation therapeutique |
| EP1074617A2 (en) * | 1999-07-29 | 2001-02-07 | Helix Research Institute | Primers for synthesising full-length cDNA and their use |
| WO2001075177A2 (en) * | 2000-04-03 | 2001-10-11 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tumor markers in ovarian cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5298614A (en) * | 1986-01-06 | 1994-03-29 | Nippon Shinyaku Co. Ltd. | Size limited double stranded poly I poly(cytidylate/4-thiouridylate) |
| CA2203843C (en) * | 1997-04-28 | 2013-07-23 | Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence | Liposome-encapsulated poly iclc |
| CA2238656A1 (en) * | 1998-05-22 | 1999-11-22 | Universite De Montreal | Mammalian staufen and use thereof |
| WO2001007471A2 (en) * | 1999-07-21 | 2001-02-01 | Incyte Genomics, Inc. | Cell cycle and proliferation proteins |
-
2002
- 2002-09-02 WO PCT/JP2002/008856 patent/WO2003023031A1/ja not_active Application Discontinuation
- 2002-09-02 EP EP02762944A patent/EP1435389A4/en not_active Withdrawn
- 2002-09-02 JP JP2003527096A patent/JPWO2003023031A1/ja active Pending
- 2002-09-02 CA CA002459373A patent/CA2459373A1/en not_active Abandoned
- 2002-09-04 US US10/233,553 patent/US20030125285A1/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62252798A (ja) * | 1986-01-06 | 1987-11-04 | Nippon Shinyaku Co Ltd | 核酸誘導体 |
| JPH01238597A (ja) * | 1987-07-03 | 1989-09-22 | Nippon Shinyaku Co Ltd | 核酸誘導体 |
| WO1999020283A1 (fr) * | 1997-10-16 | 1999-04-29 | Nippon Shinyaku Co., Ltd. | Activateur de nuclease de cellules intracancereuses |
| WO1999048531A1 (fr) * | 1998-03-24 | 1999-09-30 | Nippon Shinyaku Co., Ltd. | Nouveaux remedes contre l'hepatite |
| WO1999061032A1 (fr) * | 1998-05-25 | 1999-12-02 | Nippon Shinyaku Co., Ltd. | Procede de production d'une preparation composite contenant de l'acide nucleique |
| WO2000060073A1 (fr) * | 1999-03-31 | 2000-10-12 | Sumitomo Pharmaceuticals Co., Ltd. | Gene de polypeptide irg27, anticorps contre ce polypeptide et son utilisation therapeutique |
| EP1074617A2 (en) * | 1999-07-29 | 2001-02-07 | Helix Research Institute | Primers for synthesising full-length cDNA and their use |
| WO2001075177A2 (en) * | 2000-04-03 | 2001-10-11 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tumor markers in ovarian cancer |
Non-Patent Citations (5)
| Title |
|---|
| DATABASE MEDLINE [online] NATIONAL LIBRARY OF MEDICINE; HIRABAYASHI K. ET AL.: "Inhibition of metastatic carcinoma cell growth in livers by poly(I): poly(C)/cationic liposome complex", XP002959830, accession no. NCBI Database accession no. 10905561 * |
| GATIGNOL A. ET AL.: "Relatedness of an RNA-binding motif in human immunodeficiency virus type 1 TAR RNA-binding protein TRBP to human P1/dsI kinase and drosophila staufen", MOL. CELL. BIOL., vol. 13, 1993, pages 2193 - 2202, XP002959831 * |
| HIRABAYASHI K. ET AL.: "Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex a new biological activity", CANCER RESEARCH, vol. 59, 1999, pages 4325 - 4333, XP002959832 * |
| ONCOL. RES., vol. 11, no. 11-12, 1999, pages 497 - 504 * |
| See also references of EP1435389A4 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007269886A (ja) * | 2006-03-30 | 2007-10-18 | Fujifilm Corp | 感光性重合体、感光性組成物及び平版印刷版原版 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1435389A1 (en) | 2004-07-07 |
| EP1435389A4 (en) | 2006-02-22 |
| US20030125285A1 (en) | 2003-07-03 |
| CA2459373A1 (en) | 2003-03-20 |
| JPWO2003023031A1 (ja) | 2004-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03010402A (es) | Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina. | |
| BR0314236A (pt) | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos | |
| NZ601544A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| WO2003051388A3 (en) | Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases | |
| WO2001038503A3 (en) | Novel human protein kinases and protein kinase-like enzymes | |
| WO2003000343A3 (en) | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | |
| BR0308137A (pt) | Formulações de droga de liberação constante contendo um peptìdeo veìculo | |
| WO1997035591B1 (en) | Method of treating ciliary dyskinesia with uridine triphosphates and related compounds | |
| BR0308196A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase cinase-3, e de doenças, e, processo para a preparação de um composto | |
| WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| MXPA03006217A (es) | Sistema de administracion espaciada de farmacos. | |
| IL156780A0 (en) | Modular transfection systems | |
| PT1272199E (pt) | Terapias de combinacao com actividade de lesao vascular | |
| WO1999015643A3 (en) | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE | |
| WO2001066594A3 (en) | Human protein kinases and protein kinase-like enzymes | |
| IL121272A0 (en) | Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug | |
| BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
| BR9912609A (pt) | Métodos de uso de um análogo de somatostatina | |
| Schwartz et al. | Schedule-dependent synergy and antagonism between high-dose 1-β-d-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia | |
| WO2003023031A1 (fr) | Methode d'evaluation de l'efficacite d'une therapie aux acides nucleiques | |
| WO2005013802A3 (en) | Trefoil factor 3 (tff3) as a target for anti-cancer therapy | |
| HK1052726A1 (zh) | 人类蛋白激酶及类似蛋白激酶的酵素 | |
| AU2003227593A1 (en) | New analogs of nitrobenzylthioinosine | |
| WO2003072606A3 (en) | Galectin-8and functional derivatives as binding agents for cd44 glycoproteins and methods of use | |
| BRPI0508053A (pt) | método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2003527096 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2459373 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002762944 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002762944 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2002762944 Country of ref document: EP |